Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TLPPFBullishCorporate Developmentsnews

High materiality8/10

Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure

Jan 21, 2026, 2:36 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Despite a challenging market, strong revenue and analyst ratings suggest potential upside. Previous instances, like similar company recoveries post-revenue growth, provide a precedent.

AI summary

What happened, with direct paths to the underlying reporting

Telix Pharmaceuticals reported aligned FY 2025 revenue of $804 million, with a strong fourth quarter performance. The U.S. launch of Gozellix supported this growth, and analysts remain optimistic despite the stock's significant decline over the past year. The stock's mixed momentum indicators suggest potential volatility ahead.

Telix Pharmaceuticals reported $804 million in FY 2025 revenue.
Fourth quarter revenue increased by 46% year-over-year to $208 million.
Gozellix launched successfully following CMS reimbursement approval effective October 1, 2025.
Company shows mixed momentum; stock down 56.91% over the last year.
Analysts maintain a Buy rating with a price target averaging $21.20.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure

Telix to Acquire ITM Isotope Munich for $1.65B, Expanding Radiopharmaceutical Platform

Telix Therapeutics Targets Key Approval with TLX101-Px in Glioma Imaging

Telix Shows Strong Growth; Analyst Reiterates $22 Price Target

Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance